Table 1 Covariate comparison between groups before and after propensity score matching.

From: Clinical and economic outcomes of a pharmacogenomics-enriched comprehensive medication management program in a self-insured employee population

Variable

Participants (n = 455)

Non-participants (n = 1625)

P-value

Std mean diff

Intervention (n = 452)

Matched control group (n = 1500)

P-value

Std mean diff

Demographics

Age

53

52.7

0.644

0.21

52.9

52.9

0.85

0.01

Sex

  Male

26.6%

24.7%

0.46

0.02

26.3%

25.8%

0.53

0.01

  Female

73.4%

75.3%

 

0.04

73.7%

74.0%

 

0.01

Zip code region (0–9)

  0

10.6%

10.3%

0.56

0.01

10.4%

10.6%

0.89

0.01

  1

7.5%

9.0%

 

0.06

7.5%

7.7%

 

0.01

  2

13.6%

11.3%

 

0.07

13.7%

13.6%

 

0.00

  3

17.4%

18.7%

 

0.03

17.5%

17.6%

 

0.00

  4

10.3%

8.0%

 

0.08

10.2%

10.5%

 

0.01

  5

1.0%

1.0%

 

0.01

1.0%

1.0%

 

0.01

  6

10.6%

12.1%

 

0.05

10.6%

10.8%

 

0.01

  7

15.6%

17.4%

 

0.05

15.7%

15.2%

 

0.01

  8

5.3%

4.1%

 

0.05

5.1%

5.0%

 

0.01

  9

8.6%

8.4%

 

0.01

8.6%

8.3%

 

0.01

Risk Factors

 Number of meds

12.7

12.3

0.28

0.06

12.6

12.6

0.43

0.00

 Number of PGx meds

4.3

4

0.04

0.11

4.2

4.2

0.14

0.00

 Baseline medical cost (PMPM)

1515.85

2117.47

0.03

0.18

1501.43

1558.62

0.87

0.02

 CCI

1.5

1.6

0.68

0.02

1.5

1.6

0.63

0.02

  1. CCI Charlson Comorbidity Index, PMPM per member per month, PGx Pharmacogenomics.